secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001104659-24-122282
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov
-----------------------------------------------------------------

- Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.
- LUMUS is a global, randomized, double-blind, placebo-controlled Phase 2 trial.
- Company states the revisions conform with prior SEC filings and public guidance.
- No specific new dates or financial impact disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/0001104659-24-122282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/tm2429434d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-122282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer